Presentations Featured News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentations featured. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentations Featured Today - Breaking & Trending Today

Biogen Inc.: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high ....

United States , United Kingdom , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Shibeshih Belachew , Ashleigh Koss , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Program Database , Commitment To Health , Biogen Digital Health , Six Week Administration , Acariahealth Specialty Pharmacy Program , Exchange Commission , American Academy Of Neurology , Ms With Digital Health Research , American Academy , Chief Medical Officer , Every Six Week , Unified Commitment , World Analyses Further Demonstrate High Rates , Continues Pursuit , Biogen Digital ,

New Data at AAN 2022 Highlight Real-World Evidence from

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every. ....

United States , United Kingdom , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Shibeshih Belachew , Ashleigh Koss , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Program Database , Biogen Digital Health , Six Week Administration , Biogen Inc , Research In Multiple Sclerosis , Commitment To Health , Acariahealth Specialty Pharmacy Program , Exchange Commission , American Academy Of Neurology , Ms With Digital Health Research , European Committee For Treatment , American Academy , Chief Medical Officer , Every Six Week , Unified Commitment ,

Biogen Inc.: New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower ....

United States , United Kingdom , John Foley , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , Zhovtis Ryerson , Ashleigh Koss , Robert Naismith , Mike Hencke , Kenneth Murray , American Academy Of Neurology Virtual Annual Meeting , Program Database , Washington University School Of Medicine , Exchange Commission , Commitment To Health Prescribing Program , European Union , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Chief Medical Officer , Secondary Endpoints , Exploratory Outcomes , Include Evaluation ,

Biogen Inc.: Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Biogen Inc.: Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
(nusinersen)
Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA
CAMBRIDGE, Mass., April 19, 2021Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA
(nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. These data are being presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. ....

United Kingdom , United States , Charles Weissmann , Walter Gilbert , Heinz Schaller , Alfred Sandrock Jr , David Caouette , Mike Hencke , Konectom Smartphone , Kenneth Murray , Head Of Research , Ionis Pharmaceuticals Inc , Biogen Inc , Exchange Commission , American Academy Of Neurology , Ionis Pharmaceuticals , National Institute Of Neurological Disorders , American Academy , Annual Meeting , Alfred Sandrock , Optimize Treatment , Digital Tools , Enhance Disease , Presentations Featured , Controlled Study , Participants With Spinal Muscular Atrophy ,

New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile
Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab
CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life benefits and analyses of extended interval dosing (EID) with TYSABRI
® (natalizumab) as well as new real-world experience data from VUMERITY
® (diroximel fumarate). The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS. ....

United States , United Kingdom , Maha Radhakrishnan , Charles Weissmann , Walter Gilbert , Heinz Schaller , David Caouette , Mike Hencke , Diroximel Fumarate , Kenneth Murray , Program Database , Ms Partners Advancing Technology , Biogen Inc , Exchange Commission , Partners Advancing Technology , European Union , American Academy Of Neurology , Biogen Continues Leading Research , Health Solutions , American Academy , Annual Meeting , Chief Medical Officer , Demonstrate Improved Quality , Life Outcomes , Further Evaluate Extended Interval Dosing , Neurological Disorders ,